Ralliant (NYSE:RAL) SVP Karen Bick Sells 6,062 Shares

Ralliant Corporation (NYSE:RAL) SVP Karen Bick sold 6,062 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $72.00, for a total value of $436,464.00. Following the sale, the senior vice president directly owned 31,668 shares in the company, valued at approximately $2,280,096. This trade represents a 16.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ralliant Price Performance

Shares of NYSE RAL traded down $2.54 during mid-day trading on Tuesday, reaching $69.42. The company had a trading volume of 1,336,205 shares, compared to its average volume of 1,694,804. The firm has a market cap of $7.68 billion, a price-to-earnings ratio of -6.40, a PEG ratio of 2.69 and a beta of 1.61. The business’s 50-day simple moving average is $68.82 and its 200 day simple moving average is $55.58. Ralliant Corporation has a one year low of $37.27 and a one year high of $75.41. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.00 and a current ratio of 1.52.

Ralliant (NYSE:RAL) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.63 by $0.05. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. The firm had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, research analysts predict that Ralliant Corporation will post 2.87 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Tuesday, September 8th will be given a dividend of $0.05 per share. The ex-dividend date is Tuesday, September 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Ralliant’s dividend payout ratio (DPR) is currently -1.84%.

Institutional Trading of Ralliant

A number of hedge funds have recently added to or reduced their stakes in RAL. Empowered Funds LLC acquired a new position in shares of Ralliant during the second quarter worth $8,262,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Ralliant during the 2nd quarter valued at $2,474,000. Corient Private Wealth LP bought a new stake in Ralliant during the 2nd quarter worth $2,570,000. Bank of America Corp DE bought a new stake in Ralliant during the 2nd quarter worth $42,001,000. Finally, Freestone Grove Partners LP acquired a new position in Ralliant in the 2nd quarter worth about $15,211,000.

Analysts Set New Price Targets

Several brokerages have commented on RAL. Morgan Stanley boosted their price objective on shares of Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a research report on Tuesday, June 23rd. Truist Financial reiterated a “buy” rating and issued a $82.00 price target (up from $68.00) on shares of Ralliant in a research note on Friday, July 31st. Evercore initiated coverage on Ralliant in a report on Tuesday, June 9th. They set an “outperform” rating and a $80.00 price target for the company. Citigroup upped their price objective on Ralliant from $81.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, Wall Street Zen cut Ralliant from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $75.70.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.